

Antidepressants - Washington Prior Authorization Request Form

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826.

This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

	mation							
First Name:	Last Name:			Membe	Member ID:			
Address:								
City:	State:			ZIP Co	ZIP Code:			
Phone:	DOB:	DOB:			Allergies:			
Primary Insurance Information	(if any):	,				-		
Is the requested medicati	ion: New or	Continua	tion of Ther	apy? If continuation,	list sta	rt date: _		
Is this patient currently h	ospitalized?	Yes □ No	If recently	discharged, list disc	harge	date:		
Section B - Provider Infor First Name:	mation		Last Name:				M.D./D.O.	
Address:			City:		State:		ZIP code:	
Phone:	Fax:		NPI #:			Specialty:		
Office Contact Name / Fax atte	 ention to:		<u> </u>					
Section C - Medical Inforn	nation							
Medication:						Strength:		
Directions for use:						Quantity:		
Diagnosis (Please be specific	& provide as mucr	1 information	as possible):			ICD-10 Co	ODE:	
Is this member pregnant?	Yes □ No	If yes	, w hat is this	member's due date? _				
	ication Trials							
Section D - Previous Med	ication mais		Medication Name Strength Directions Dates of Therap				· · · · · · · · · · · · · · /	
		Dire	ctions	Dates of Therap	ру		n for failure / Intinuation	
		Dire	ctions	Dates of Therap	py			
		Dire	ections	Dates of Therap	ру			
		Dire	ections	Dates of Therap	ру			
		Dire	ections	Dates of Therap	py			
Medication Name	Strength					disco	ntinuation	
	Strength ormation and Ex	xplanation	of why pref		ould no	disco	ntinuation	
Medication Name	Strength ormation and Ex	xplanation	of why pref	erred medications w	ould no	disco	ntinuation	
Medication Name	Strength ormation and Ex	xplanation	of why pref	erred medications w	ould no	disco	ntinuation	
Medication Name	Strength ormation and Ex	xplanation	of why pref	erred medications w	ould no	disco	ntinuation	
Medication Name	Strength ormation and Ex	xplanation	of why pref	erred medications w	ould no	disco	ntinuation	
Medication Name	Strength ormation and Ex	xplanation	of why pref	erred medications w	ould no	disco	ntinuation	
Medication Name	Strength ormation and Ex	xplanation	of why pref	erred medications w	ould no	disco	ntinuation	
Medication Name	Strength ormation and Ex	xplanation	of why pref	erred medications w	ould no	disco	ntinuation	



Antidepressants - Washington Prior Authorization Request Form

Member First name:		Member L	ast name:	Member DOB:	Member DOB:	
Clinical and Drug Specific Information						
ALL REQUESTS						
□ Yes □ No	Is the patient transitioning from one antidepressant to another or will the patient remain on both medications? (If yes, check which applies) □ Patient will remain on both medications					
□ Yes □ No	Will the patient remain on five or more psychotropic/mental health medications or is the patient titrating/changing medications and will be on less than five psychotropic/mental health medications? (Check which applies)					
□ Yes □ No	Is the pati	ient currently on the requ	rested drug? If yes,	list start date:		
□ Yes □ No	Is the patient currently receiving treatment with the requested non-preferred behavioral health medication in the hospital and must continue upon discharge? If yes, list start date and discharge date:					
□ Yes □ No	Yes Does the patient have a history of failure, contraindication or intolerance to any alternatives from at least two of the following classes: (If yes, check which applies and complete Section D above) Alpha-2 Receptor Antagonists (Tetracyclics) Norepinephrine-Dopamine Reuptake Inhibitors Selective Serotonin Reuptake Inhibitor (SSRI) Selective Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)					
□ Yes □ No	□ Trial of t □ Trial of t	•	ner than the generic eneric eneric enering require product being require	equivalent to the requested brand sested from 5 manufacturers. ers) Generic Manufacturer		
SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI)						
□ Yes □ No Is the patient using the requested medication with a Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin Norepinephrine Reuptake Inhibitor (SNRI), or Serotonin Modulator–Miscellaneous (SMM)? (If yes, complete Section D above)						
	TETRACYCLIC ANTIDEPRESSANTS					
□ Yes □ No Is the patient using the requested medication with an Alpha-2 Receptor Antagonists–Tetracyclics (TeCA), Norepinephrine–Dopamine Reuptake Inhibitor (NDRI), Serotonin Norepinephrine Reuptake Inhibitor (SNRI), or Serotonin Modulator–Miscellaneous (SMM)? (If yes, complete Section Dabove)					take	
NDRI (BUPROPION)						
□ Yes □ No	Inhibitor (ient using the requested NDRI) or an Alpha-2 Rec mplete Section D above)		other Norepinephrine-Dopamine Reuptak etracyclics (TeCA)?	(e	



Antidepressants - Washington Prior Authorization Request Form

Member First name:		Member Last name:	Member DOB:			
SEROTONIN MODULATOR-MISCELLANEOUS (SMM)						
□ Yes □ No	Is the patient using the requested medication with a Selective Serotonin Reuptake Inhibitor (SSRI), Alpha-2 Receptor Antagonists-Tetracyclics (TeCA), Serotonin Norepinephrine Reuptake Inhibitor (SNRI), or Serotonin Modulator-Miscellaneous (SMM)? (If yes, complete Section D above)					
SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR (SNRI)						
□ Yes □ No	Is the patient using the requested medication with a Selective Serotonin Reuptake Inhibitor (SSRI), Alpha-2 Receptor Antagonists-Tetracyclics (TeCA), Serotonin Norepinephrine Reuptake Inhibitor (SNRI), or Serotonin Modulator-Miscellaneous (SMM)? (If yes, complete Section D above)					
CONTINUATION OF THERAPY						
□ Yes □ No	Is there documentation If yes, list response:	of positive clinical response to treatme	ent?			
Provider Signature: Date:						

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.